Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Blocklisting Interim Review

17 Aug 2015 09:14

RNS Number : 2142W
GW Pharmaceuticals PLC
17 August 2015
 



 

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS APPROVED SHARE OPTION SCHEME 2001

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2015 TO: 17 AUGUST 2015

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

119,050 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

72,150 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

46,900 ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

516,558 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

200,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

200,000 ORDINARY SHARES OF 0.1P EACH ON 29 NOVEMBER 2013

122,613 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

261,087,473 ORDINARY SHARES OF 0.1P EACH

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS UNAPPROVED SHARE OPTION SCHEME 2001

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2015 TO: 17 AUGUST 2015

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

312,451 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

755,473 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

56,978 ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

1,279,192 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

500,000 ORDINARY SHARES OF 0.1P EACH ON 24 MAY 2011

800,000 ORDINARY SHARES OF 0.1P EACH ON 29 NOVEMBER 2013

500,000 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

500,000 ORDINARY SHARES OF 0.1P EACH ON 9 JANUARY 2015

500,000 ORDINARY SHARES OF 0.1P EACH ON 5 JUNE 2015

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

261,087,473 ORDINARY SHARES OF 0.1P EACH

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS EXECUTIVE SHARE OPTION SCHEME

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2015 TO: 17 AUGUST 2015

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

208,550 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

2,800 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

205,750 ORDINARY SHARES OF 0.1P EACH.

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

1,388,375 ORDINARY SHARES OF 0.1P EACH ON 7 OCTOBER 2003

300,000 ORDINARY SHARES OF 0.1P EACH ON 23 APRIL 2008

400,000 ORDINARY SHARES OF 0.1P EACH ON 18 JANUARY 2010

400,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

300,000 ORDINARY SHARES OF 0.1P EACH ON 24 MAY 2011

168,650 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

261,087,473 ORDINARY SHARES OF 0.1P EACH

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS LONG TERM INCENTIVE PLAN 2008

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2015 TO: 17 AUGUST 2015

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

784,451 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

1,021,408 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

763,043 ORDINARY SHARES OF 0.1P EACH.

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

600,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

300,000 ORDINARY SHARES OF 0.1P EACH ON 29 NOVEMBER 2013

500,000 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

1,000,000 ORDINARY SHARES OF 0.1P EACH ON 5 JUNE 2015

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

261,087,473 ORDINARY SHARES OF 0.1P EACH

 

 

 

For further information, please contact:

 

Adam George, Company Secretary, GW Pharmaceuticals plc

 

Telephone: +44 (0)1223 266800

 

James Steel/Clare Terlouw, Nominated Adviser, Peel Hunt LLP

 

Telephone: +44 (0)20 7418 8900

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRVDLBFEVFFBBX
Date   Source Headline
10th May 20134:24 pmRNSHolding(s) in Company
9th May 20133:40 pmRNSTotal Voting Rights
8th May 20138:00 amRNSClosing of Initial Public Offering on Nasdaq
7th May 20137:00 amRNSSativex Commercialization Approval in Italy
1st May 20135:47 pmRNSPricing of U.S. Initial Public Offering
22nd Apr 20137:00 amRNSUS Patent Allowance for SATIVEX Formulation Spray
18th Apr 20132:23 pmRNSAmendment to Registration Statement for NASDAQ
12th Apr 201310:31 amRNSResults of General Meeting
10th Apr 20137:00 amRNSSativex moved to Schedule 4 of UK Drugs Act
3rd Apr 20137:00 amRNSNew US Patent Allowance for Delivery of SATIVEX
22nd Mar 20132:35 pmRNSPosting of Shareholder Circular
19th Mar 20132:46 pmRNSAppoints Stephen Schultz VP of Investor Relations
19th Mar 20131:10 pmRNSUpdate on Sativex in Germany
19th Mar 20131:01 pmRNSFiling for listing on NASDAQ
19th Feb 20133:16 pmRNSDirectorate Change
19th Feb 20139:30 amRNSBlocklisting Interim Review
4th Dec 201210:04 amRNSDirector/PDMR Shareholding
30th Nov 20122:54 pmRNSDirector/PDMR Shareholding
30th Nov 20122:50 pmRNSDirector/PDMR Shareholding
28th Nov 20127:00 amRNSPreliminary Results
28th Nov 20127:00 amRNSPhIIa Study Identifies New Anti-Diabetic Treatment
22nd Nov 201211:31 amRNSNotice of Results
12th Nov 20127:00 amRNSGW to Present at Lazard Healthcare Conference
12th Oct 20127:00 amRNSPositive German Sativex Data Presented at ECTRIMS
1st Oct 20127:00 amRNSAppointment of Chief Operating Officer
13th Sep 20127:00 amRNSPublication of New Epilepsy Data
20th Aug 201212:14 pmRNSDirector/PDMR Shareholding
17th Aug 20124:04 pmRNSBlocklisting Interim Review
22nd Jun 20127:00 amRNSGerman GBA establishes positive benefit of Sativex
13th Jun 201210:19 amRNSDirector/PDMR Shareholding
6th Jun 20124:03 pmRNSDirector/PDMR Shareholding
23rd May 20123:56 pmRNSDirector/PDMR Shareholding
22nd May 20127:00 amRNSThird Cancer Pain Trial Commences
22nd May 20127:00 amRNSInterim Results
8th May 20127:00 amRNSSuccessful completion of MRP for Sativex
26th Apr 201211:00 amRNSNotice of Results
23rd Apr 20127:00 amRNSSativex phase IIb pain trial results publication
16th Apr 20127:00 amRNSAlmirall Milestone
5th Apr 20127:00 amRNSBoard Changes
2nd Apr 20122:31 pmRNSDirector/PDMR Shareholding
30th Mar 20121:57 pmRNSDirector/PDMR Shareholding
15th Mar 20127:00 amRNSGW and Almirall Strengthen Strategic Collaboration
8th Mar 20127:00 amRNSAppointment of Professor Vincenzo Di Marzo
17th Feb 20127:00 amRNSBlocklisting Interim Review
7th Feb 20127:00 amRNSSATIVEX® Regulatory Approval Received in Austria
25th Jan 20121:46 pmRNSResult of AGM
11th Jan 201211:43 amRNSHolding(s) in Company
11th Jan 201211:42 amRNSHolding(s) in Company
28th Dec 201110:39 amRNSDirector/PDMR Shareholding
22nd Dec 20117:00 amRNSSativex Approval in Sweden

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.